TDMS No. 05174 - 06 Test Type: CHRONIC Route: DOSED FEED

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

CRESOLS

CAS Number: 1319-77-3
Pathologist: BOYCE, J. - TOFT, J.

f1_M3_Females

C Number: C62260B

Lock Date: 01/21/2005

Cage Range: ALL

Date Range: ALL

Reasons For Removal: ALL

Removal Date Range: ALL

Treatment Groups: Include ALL

Date Report Reqsted: 05/03/2006 Time Report Reqsted: 14:33:38 First Dose M/F: NA / 08/20/02

Lab: BAT

CRESOLS

CAS Number: 1319-77-3

Pathologist: BOYCE, J. - TOFT, J.

Lab: BAT

Date Report Reqsted: 05/03/2006

Time Report Reqsted: 14:33:38

First Dose M/F: NA / 08/20/02

B6C3F1 MICE FEMALE	0 PPM	1000 PPM	3000 PPM	10000 PPM	
Disposition Summary					
Animals Initially in Study Early Deaths	50	50	50	50	
Moribund Sacrifice Natural Death	4 5	4 3	5	1 7	
Survivors	· ·	O .	O .	•	
Terminal Sacrifice	41	43	44	42	
Missing			1		
Animals Examined Microscopically	50	50	49	50	
ALIMENTARY SYSTEM					
Esophagus	(50)	(50)	(49)	(50)	
Gallbladder	(50)	(50)	(49)	(50)	
Cyst Infiltration Cellular, Lymphoid	6 (12%)	1 (2%) 10 (20%)	6 (12%)	9 (18%)	
Inflammation, Chronic Active Intestine Large, Colon	(49)	1 (2%) (50)	(49)	(50)	
Thrombosis	1 (2%)	(66)	(10)	(66)	
Intestine Large, Rectum	(49)	(50)	(49)	(50)	
Intestine Small, Ileum	(50)	(50)	(49)	(50)	
Intestine Small, Jejunum	(50)	(50)	(49)	(50)	
Inflammation, Chronic Active		1 (2%)	1 (2%)		
Epithelium, Ulcer		0 (40()	1 (2%)		
Peyer's Patch, Hyperplasia, Lymphoid	(50)	2 (4%)	1 (2%)	(50)	
Liver Angiectasis	(50) 1 (2%)	(50)	(49) 1 (2%)	(50) 1 (2%)	
Arigieciasis Atrophy	1 (2%)	1 (2%)	I (270)	I (∠/0)	
Basophilic Focus	3 (6%)	1 (2%)	3 (6%)	1 (2%)	
Clear Cell Focus	3 (370)	1 (2%)	3 (375)	1 (2%)	
Eosinophilic Focus	1 (2%)	. (-,-)	2 (4%)	12 (24%)	
Hematopoietic Cell Proliferation		1 (2%)	1 (2%)	1 (2%)	
Infiltration Cellular, Lymphoid	40 (80%)	43 (86%)	39 (80%)	42 (84%)	
Inflammation, Chronic Active	43 (86%)	44 (88%)	43 (88%)	43 (86%)	
Mixed Cell Focus				1 (2%)	
Pigmentation	2 (4%)	- ()	- ()	. (155)	
Tension Lipidosis	8 (16%)	3 (6%)	6 (12%)	8 (16%)	
Bile Duct, Cyst	1 (2%)			1 (2%)	

TDMS No. 05174 - 06

Test Type: CHRONIC

Route: DOSED FEED

a - Number of animals examined microscopically at site and number of animals with lesion

CRESOLS

CAS Number: 1319-77-3

Pathologist: BOYCE, J. - TOFT, J.

Date Report Reqsted: 05/03/2006 Time Report Reqsted: 14:33:38 First Dose M/F: NA / 08/20/02

Lab: BAT

B6C3F1 MICE FEMALE	0 PPM	1000 PPM	3000 PPM	10000 PPM	
Bile Duct, Cyst, Multiple				1 (2%)	
Centrilobular, Hepatocyte, Degeneration	1 (2%)			. (=/5)	
Hepatocyte, Necrosis	1 (2%)	1 (2%)	1 (2%)		
Hepatocyte, Vacuolization Cytoplasmic	3 (6%)	4 (8%)	1 (2%)	1 (2%)	
Mesentery	(6)	(3)	(5)	(5)	
Fat, Infiltration Cellular, Lymphoid	()	()	()	1 (20%)	
Fat, Inflammation, Chronic Active		1 (33%)		,	
Fat, Necrosis	4 (67%)	2 (67%)	1 (20%)	1 (20%)	
Oral Mucosa	(0)	(1)	(0)	(0)	
Gingival, Foreign Body	. ,	1 (100%)		,	
Gingival, Inflammation, Chronic Active		1 (100%)			
Pancreas	(50)	(50)	(49)	(50)	
Basophilic Focus		•	1 (2%)	1 (2%)	
Infiltration Cellular, Lymphoid	21 (42%)	23 (46%)	25 (51%)	24 (48%)	
Inflammation, Chronic Active	1 (2%)	3 (6%)			
Polyarteritis		1 (2%)			
Acinus, Atrophy	1 (2%)	2 (4%)	1 (2%)		
Duct, Cyst	1 (2%)	3 (6%)	1 (2%)	1 (2%)	
Duct, Cyst, Multiple		1 (2%)			
Duct, Inflammation, Chronic Active		1 (2%)			
Salivary Glands	(50)	(50)	(49)	(49)	
Infiltration Cellular, Lymphoid	34 (68%)	36 (72%)	34 (69%)	21 (43%)	
Stomach, Forestomach	(49)	(49)	(49)	(49)	
Epithelium, Hyperplasia				2 (4%)	
Stomach, Glandular	(50)	(50)	(49)	(50)	
Mineralization	2 (4%)	3 (6%)	3 (6%)	1 (2%)	
Tooth	(2)	(0)	(2)	(0)	
Malformation	1 (50%)		1 (50%)		
RDIOVASCULAR SYSTEM					
Blood Vessel	(50)	(50)	(49)	(50)	
Aorta, Mineralization		1 (2%)			
Heart	(50)	(50)	(49)	(50)	
Mineralization	2 (4%)	1 (2%)		1 (2%)	
Polyarteritis		1 (2%)			
Valve, Inflammation, Chronic Active		1 (2%)			

ENDOCRINE SYSTEM

TDMS No. 05174 - 06

Test Type: CHRONIC

Route: DOSED FEED

a - Number of animals examined microscopically at site and number of animals with lesion

CRESOLS

CAS Number: 1319-77-3

Pathologist: BOYCE, J. - TOFT, J.

Date Report Reqsted: 05/03/2006 Time Report Reqsted: 14:33:38 First Dose M/F: NA / 08/20/02

Lab: BAT

B6C3F1 MICE FEMALE	0 PPM	1000 PPM	3000 PPM	10000 PPM	
Adrenal Cortex	(49)	(50)	(49)	(50)	
Accessory Adrenal Cortical Nodule	1 (2%)	(00)	(10)	1 (2%)	
Hematopoietic Cell Proliferation	1 (270)	1 (2%)		1 (270)	
Hypertrophy	1 (2%)	1 (2%)		1 (2%)	
Infiltration Cellular, Lymphoid	. (278)	. (273)		1 (2%)	
Vacuolization Cytoplasmic		2 (4%)		1 (2%)	
Subcapsular, Hyperplasia	48 (98%)	50 (100%)	48 (98%)	50 (100%)	
Adrenal Medulla	(49)	(50)	(49)	(50)	
Hyperplasia	3 (6%)	(00)	(10)	1 (2%)	
Islets, Pancreatic	(50)	(50)	(49)	(50)	
Parathyroid Gland	(39)	(44)	(40)	(45)	
Cyst	1 (3%)	1 (2%)	(10)	(10)	
Cyst, Multiple	1 (3%)	1 (2%)			
Bilateral, Cyst	. (0,0)	. (= /3)	1 (3%)		
Pituitary Gland	(50)	(50)	(49)	(50)	
Pars Distalis, Cyst, Multiple	1 (2%)	(00)	(10)	(00)	
Pars Distalis, Hyperplasia	7 (14%)	7 (14%)	3 (6%)	2 (4%)	
Thyroid Gland	(48)	(48)	(49)	(50)	
Ectopic Thymus	(10)	1 (2%)	1 (2%)	2 (4%)	
Infiltration Cellular, Lymphoid		1 (2%)	(=75)	_ (· · · ·)	
Inflammation, Chronic Active		()	2 (4%)	3 (6%)	
Polyarteritis		1 (2%)	(/	- ()	
Follicle, Cyst	1 (2%)	1 (2%)	2 (4%)	3 (6%)	
Follicle, Degeneration	7 (15%)	24 (50%)	24 (49%)	21 (42%)	
Follicular Cell, Hyperplasia	2 (4%)	, ,	,	2 (4%)	

GENERAL BODY SYSTEM

None

GENI	IAL	SYS	IEM	

TDMS No. 05174 - 06

Test Type: CHRONIC

Route: DOSED FEED

Clitoral Gland Inflammation, Chronic Active	(49) 1 (2%)	(49)	(49) 1 (2%)	(50)
Ovary	(50)	(50)	(49)	(50)
Angiectasis	1 (2%)			1 (2%)
Atrophy	49 (98%)	49 (98%)	47 (96%)	47 (94%)
Cyst	14 (28%)	9 (18%)	3 (6%)	8 (16%)
Cyst, Multiple	•			1 (2%)
Hemorrhage	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

CRESOLS

CAS Number: 1319-77-3

Pathologist: BOYCE, J. - TOFT, J.

Date Report Reqsted: 05/03/2006 Time Report Reqsted: 14:33:38 First Dose M/F: NA / 08/20/02

Lab: BAT

Thrombosis	B6C3F1 MICE FEMALE	0 PPM	1000 PPM	3000 PPM	10000 PPM	
Bilateral, Cyst						
Oviduct Uterus (0) (50) (1) (2) (50) (60) (50) (49) (50) (50) (1) (2%) (50) (1) (2%) (50) (1) (2%) (50) (1) (2%) (50) (1) (2%) (50) (49) (50) (50) (40) (40) (40) (50) (40) (40) (40) (50) (40) (40) (50) (40) (50) (50) (40) (50) (50) (50) (40) (50)			4 (00()		4 (00()	
Ulerus				(0)		
Inflammation, Suppurative		(0)		(2)	(0)	
Endometrium, Hyperplasia, Cystic		(50)	(50)		(50)	
HEMATOPOIETIC SYSTEM			40 (000()		40 (000()	
Bone Marrow	Endometrium, Hyperpiasia, Cystic	41 (82%)	46 (92%)	46 (94%)	43 (86%)	
Angiectasis 1 (2%) 1 (2%) 1 (2%) 4 (4%) Hyperplasia 1 (2%) 6 (12%) 5 (10%) 2 (4%) Myelofibrosis 23 (46%) 33 (66%) 18 (37%) 25 (50%) Lymph Node (2) (5) (7) (7) Bronchial, Hyperplasia, Lymphoid 1 (50%) 1 (20%) Iliac, Pigmentation 1 (20%) Lumbar, Congestion 1 (14%) 1 (20%) Lumbar, Ectasia 1 (49) (50) (49) (49) (49) Hyperplasia, Lymphoid 4 (8%) 4 (8%) 5 (10%) 3 (6%) Hyperplasia, Lymphoid 4 (8%) 4 (8%) 5 (10%) 3 (6%) Hyperplasia, Lymphoid 4 (8%) 5 (10%) 3 (6%) Hyperplasia, Plasma Cell 1 (2%)	HEMATOPOIETIC SYSTEM					
Angiectasis 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%)	Bone Marrow	(50)	(50)	(49)	(50)	
Hyperplasia 1 (2%) 6 (12%) 5 (10%) 2 (4%) Myelofibrosis 23 (46%) 33 (66%) 18 (37%) 25 (50%) Lymph Node (2) (5) (7) (7) Bronchial, Hyperplasia, Lymphoid 1 (50%) 1 (20%) Liliac, Pigmentation 1 (14%) Lumbar, Congestion 1 (14%) Lumbar, Ectasia 1 (14%) Mediastinal, Hyperplasia, Lymphoid 4 (8%) 4 (8%) 5 (10%) 3 (6%) Hyperplasia, Lymphoid 4 (8%) 4 (8%) 5 (10%) 3 (6%) Hyperplasia, Lymphoid 4 (8%) 4 (8%) 5 (10%) 3 (6%) Hyperplasia, Lymphoid 4 (8%) 5 (10%) 3 (6%) Hyperplasia, Lymphoid 4 (8%) 5 (10%) 7 (14%) Hyperplasia, Lymphoid 4 (8%) 5 (10%) 7 (14%) Hyperplasia, Lymphoid 4 (8%) 1 (2%) 1 (2%) Lymph Node, Masenteric (48) (50) (48) (49) Hyperplasia, Lymphoid 4 (8%) 1 (2%) 7 (14%) Hyperplasia, Lymphoid 1 (2%) 1 (2%) 7 (14%) Hyperplasia, Lymphoid 1 (48) (50) (49) (50) Atrophy 1 (2%) 1 (2%) 1 (2%) Lymphoid Follicle, Hyperplasia 1 4 (29%) 13 (26%) 16 (33%) 12 (24%) Thymus (50) (49) (50) Ectopic Parathyroid Gland 8 (16%) 10 (20%) 6 (12%) 4 (8%) Hyperplasia, Lymphoid 2 (4%) INTEGUMENTARY SYSTEM Mammary Gland (49) (50) (49) (50) Mammary Gland (49) (50) (49) (50) Skin (49) (50) (49) (50)	Angiectasis		,			
Myelofibrosis 23 (46%) 33 (66%) 18 (37%) 25 (50%) Lymph Node (2) (5) (7) (7) Bronchial, Hyperplasia, Lymphoid Iliac, Pigmentation 1 (50%) 1 (20%) 1 (14%) Lumbar, Congestion 1 (14%) 2 (29%) Lumbar, Ectasia 1 (14%) 2 (29%) Mediastinal, Hyperplasia, Lymphoid (49) (50) (49) (49) Hyperplasia, Lymphoid 4 (8%) 4 (8%) 5 (10%) 3 (6%) Hyperplasia, Lymphoid 4 (8%) 5 (10%) 3 (6%) Hyperplasia, Lymphoid 4 (8%) (50) (48) (49) Hyperplasia, Lymphoid 4 (8%) (50) (48) (49) Hyperplasia, Lymphoid 4 (8%) 1 (2%) 7 (14%) Hyperplasia, Lymphoid 4 (8%) 1 (2%) 7 (14%) Spleen (48) (50) (49) (50) Atrophy 1 (2%) 1 (2%) 1 (2%) Hymphoid Follicle, Hyperplasia 14 (29%) 13 (26%) 16 (33%)	•		6 (12%)			
Lymph Node		23 (46%)	33 (66%)			
Bronchial, Hyperplasia, Lymphoid						
Iliac, Pigmentation		1 (50%)		,	,	
Lumbar, Congestion Lumbar, Ectasia Mediastinal, Hyperplasia, Lymphoid Lymph Node, Mandibular Hyperplasia, Lymphoid Hyperplasia, Plasma Cell Lymph Node, Mesenteric Hyperplasia, Lymphoid Hyperplasia, Plasma Cell Lymph Node, Mesenteric Hyperplasia, Plasma Cell Lymph Node, Mesenteric Hyperplasia, Plasma Cell Hyperplasia, Plasma Cell Lymph Node, Mesenteric Hyperplasia, Plasma Cell Hyperplasia Higher Hyperplasia Higher Hyperplasia Higher Hyperplasia Higher Hyperplasia Higher Hyperplasia Higher Hyperplasia Higher Hyperplasia Hyperplasia Higher Hyperplasia Higher Hyperplasia Hyperplasia Higher Higher Higher Higher Higher Higher Higher Higher H		,	1 (20%)			
Lumbar, Ectasia Mediastinal, Hyperplasia, Lymphoid Lymph Node, Mandibular Hyperplasia, Lymphoid Hyperplasia, Lymphoid Hyperplasia, Lymphoid Hyperplasia, Plasma Cell Lymph Node, Mesnetric (48) Hyperplasia, Lymphoid Hyperplasia, Lymphoid 4 (8%) Hyperplasia, Lymphoid 4 (8%) Hyperplasia, Lymphoid 4 (8%) Hyperplasia, Lymphoid 4 (8%) Hyperplasia, Plasma Cell Lymph Node, Mesenteric (48) (50) (48) (49) (49) (49) (40) (48) (50) (49) (50) (49) (50) (49) (50) (40) (50) (40) (50) (50) (50) (612%) (61			,		1 (14%)	
Lymph Node, Mandibular (49) (50) (49) (49) (49) (49) (49) (49) (49) (49					1 (14%)	
Lymph Node, Mandibular (49) (50) (49) (49) (49) (49) (49) (49) (49) (49	Mediastinal, Hyperplasia, Lymphoid			1 (14%)	2 (29%)	
Hyperplasia, Plasma Cell Lymph Node, Mesenteric Lymph Node, Mesenteric Lymph Node, Mesenteric Lymph Node, Mesenteric Lymphold Lym	Lymph Node, Mandibular	(49)	(50)	(49)	(49)	
Lymph Node, Mesenteric (48) (50) (48) (49) (7 (14%) (49) (49) (49) (49) (50) (48) (48) (49) (50) (48) (49) (50) (49) (49) (50)	Hyperplasia, Lymphoid	4 (8%)	4 (8%)	5 (10%)	3 (6%)	
Hyperplasia, Lymphoid Hyperplasia, Plasma Cell 1 (2%) Spleen (48) Atrophy 1 (2%) Hematopoietic Cell Proliferation Lymphoid Follicle, Hyperplasia Hyperplasia, Lymphoid Hyperplasia, Lymphoid 1 (2%) Hematopoietic Cell Proliferation T (15%) Lymphoid Follicle, Hyperplasia Thymus (50) Ectopic Parathyroid Gland Hyperplasia, Lymphoid 1 (2%) INTEGUMENTARY SYSTEM Mammary Gland Hyperplasia Duct, Dilatation Skin (49) (50) L1 (2%) L2 (4%) L3 (26%) L4 (8%) L5 (10%) L6 (12%) L6 (12%) L6 (12%) L6 (12%) L6 (12%) L6 (12%) L7 (49) L7 (49) L7 (14%) L7	Hyperplasia, Plasma Cell			1 (2%)		
Hyperplasia, Plasma Cell	Lymph Node, Mesenteric		(50)	(48)	(49)	
Spleen				1 (2%)		
Atrophy 1 (2%) 1 (2%)						
Hematopoietic Cell Proliferation 7 (15%) 6 (12%) 4 (8%) 6 (12%) Lymphoid Follicle, Hyperplasia 14 (29%) 13 (26%) 16 (33%) 12 (24%) 17 (20%) (49) (49) (49) (50) (49) (50) (49%) (50) (49%) (50) (49%) (50) (49%) (50%) (49%) (49				(49)	(50)	
Lymphoid Follicle, Hyperplasia 14 (29%) 13 (26%) 16 (33%) 12 (24%) Thymus (50) (49) (49) (49) (50) Ectopic Parathyroid Gland Hyperplasia, Lymphoid 2 (4%) INTEGUMENTARY SYSTEM Mammary Gland Hyperplasia Duct, Dilatation Skin (49) (50) (49) (50) (49) (50) (49) (50) (49) (50) (49) (50) (49) (50) (49) (50) (49) (50)						
Thymus (50) (49) (49) (50) (50) Ectopic Parathyroid Gland 8 (16%) 10 (20%) 6 (12%) 4 (8%) 5 (10%) INTEGUMENTARY SYSTEM Mammary Gland (49) (50) (49) (50) (49) (50) Hyperplasia 1 (2%) 1 (2%) Duct, Dilatation Skin (49) (50) (49) (50) (49) (50)						
Ectopic Parathyroid Gland						
Hyperplasia, Lymphoid 2 (4%) 5 (10%) INTEGUMENTARY SYSTEM Mammary Gland (49) (50) (49) (50) Hyperplasia 1 (2%) Duct, Dilatation 1 (2%) 1 (2%) Skin (49) (50) (49) (50)						
NTEGUMENTARY SYSTEM			10 (20%)	6 (12%)		
Mammary Gland (49) (50) (49) (50) Hyperplasia 1 (2%) 1 (2%) Duct, Dilatation 1 (2%) 1 (2%) 1 (2%) Skin (49) (50) (49) (50)	Hyperplasia, Lymphoid	2 (4%)			5 (10%)	
Hyperplasia 1 (2%) Duct, Dilatation 1 (2%) 1 (2%) Skin (49) (50) (49) (50)	INTEGUMENTARY SYSTEM					
Hyperplasia 1 (2%) Duct, Dilatation 1 (2%) 1 (2%) 1 (2%) Skin (49) (50) (49) (50)	Mammary Gland	(49)	(50)	(49)	(50)	
Duct, Dilatation 1 (2%) 1 (2%) 1 (2%) Skin (49) (50) (49) (50)		(15)	(55)		(-3)	
Skin (49) (50) (49) (50)			1 (2%)		1 (2%)	
		(49)				
	Cyst Epithelial Inclusion	(15)	1 (2%)	(13)	(-3)	

TDMS No. 05174 - 06

Test Type: CHRONIC

Route: DOSED FEED

a - Number of animals examined microscopically at site and number of animals with lesion

CRESOLS

CAS Number: 1319-77-3
Pathologist: BOYCE, J. - TOFT, J.

Date Report Reqsted: 05/03/2006 Time Report Reqsted: 14:33:38 First Dose M/F: NA / 08/20/02

Lab: BAT

B6C3F1 MICE FEMALE	0 PPM	1000 PPM	3000 PPM	10000 PPM	
MUSCULOSKELETAL SYSTEM					
Bone	(50)	(50)	(49)	(50)	
Osteopetrosis	(0)	(0)	(0)	1 (2%)	
Skeletal Muscle	(0)	(2)	(2)	(1)	
Infiltration Cellular, Lymphoid		1 (50%)	1 (50%)		
NERVOUS SYSTEM					
Brain	(50)	(50)	(49)	(50)	
Hydrocephalus	. (221)	2 (4%)	. (221)		
Infiltration Cellular, Lymphoid	1 (2%)	2 (4%)	1 (2%)		
Neuron, Necrosis	1 (2%)				
RESPIRATORY SYSTEM					
Larynx	(0)	(1)	(0)	(1)	
Lung	(50)	(50)	(49)	(50)	
Hemorrhage	1 (2%)		0 (40()	4 (00)	
Infiltration Cellular, Lymphoid		4 (00()	2 (4%)	1 (2%)	
Infiltration Cellular, Polymorphonuclear		1 (2%)		2 (60/)	
Alveolar Epithelium, Hyperplasia Alveolus, Infiltration Cellular, Histiocyte		1 (2%)	1 (2%)	3 (6%) 1 (2%)	
Bronchiole, Hyperplasia		42 (84%)	44 (90%)	47 (94%)	
Nose	(50)	(50)	(49)	(49)	
Edema	(50)	(30)	(43)	1 (2%)	
Inflammation, Chronic Active	1 (2%)	1 (2%)		1 (2%)	
Glands, Respiratory Epithelium, Dilatation	(= / 5/	(=75)		1 (2%)	
Glands, Respiratory Epithelium, Hyperplasia	6 (12%)	5 (10%)	8 (16%)	10 (20%)	
Nasolacrimal Duct, Inflammation,	2 (4%)	1 (2%)	2 (4%)	,	
Suppurative	, ,	, ,	. ,		
Olfactory Epithelium, Degeneration				1 (2%)	
Respiratory Epithelium, Degeneration				1 (2%)	
Respiratory Epithelium, Hyperplasia			28 (57%)	45 (92%)	
Respiratory Epithelium, Metaplasia,				2 (4%)	
Squamous	(2)	400	(2)	(2)	
Pleura	(0)	(1)	(0)	(0)	
Trachea	(50)	(50)	(49)	(50)	

TDMS No. 05174 - 06

Test Type: CHRONIC

Route: DOSED FEED

a - Number of animals examined microscopically at site and number of animals with lesion

CRESOLS

CAS Number: 1319-77-3

Pathologist: BOYCE, J. - TOFT, J.

Date Report Reqsted: 05/03/2006 Time Report Reqsted: 14:33:38 First Dose M/F: NA / 08/20/02

Lab: BAT

B6C3F1 MICE FEMALE	0 PPM	1000 PPM	3000 PPM	10000 PPM	
SPECIAL SENSES SYSTEM					
Eye	(50)	(50)	(49)	(50)	
Atrophy Harderian Gland	(50)	1 (2%) (50)	(48)	(50)	
Hyperplasia Infiltration Cellular, Lymphoid Inflammation, Chronic Active	1 (2%) 30 (60%)	1 (2%) 30 (60%) 1 (2%)	2 (4%) 35 (73%)	34 (68%)	
JRINARY SYSTEM					
Kidney Amyloid Deposition	(50)	(50)	(49)	(50) 1 (2%)	
Atrophy	00 (500()	1 (2%)	40 (000()	05 (500()	
Casts Protein Infarct	29 (58%) 2 (4%)	25 (50%) 2 (4%)	19 (39%) 1 (2%)	25 (50%) 3 (6%)	
Infiltration Cellular, Lymphoid	43 (86%)	2 (4%) 47 (94%)	43 (88%)	44 (88%)	
Metaplasia, Osseous	2 (4%)	4 (8%)	4 (8%)	2 (4%)	
Mineralization	2 (4%)	8 (16%)	3 (6%)	3 (6%)	
Nephropathy	14 (28%)	14 (28%)	11 (22%)	19 (38%)	
Cortex, Cyst	,	,	,	1 (2%)	
Renal Tubule, Accumulation, Hyaline Droplet Renal Tubule, Pigmentation	2 (4%)	1 (2%)	1 (2%)	1 (2%) 1 (2%)	
Urinary Bladder	(50)	(50)	(49)	(50)	
Infiltration Cellular, Lymphoid	36 (72%)	35 (70%)	43 (88%)	42 (84%)	

^{***} END OF REPORT ***

TDMS No. 05174 - 06

Test Type: CHRONIC

Route: DOSED FEED

a - Number of animals examined microscopically at site and number of animals with lesion